Search | Page 6 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Hypomethylating agents and other novel strategies in myelodysplastic syndromes.

    ... risk and no transfusion dependency, growth factors, and lenalidomide for patients with alteration of chromosome 5 and anemia ...

    Research Article last updated 07/20/2018 - 5:14pm.

  2. Myelodysplastic syndromes: What do hospitalists need to know?

    ... addition of azacitidine , decitabine , and lenalidomide to erythropoiesis-stimulating agents in our armamentarium ...

    Research Article last updated 07/20/2018 - 5:15pm.

  3. Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents.

    ... gene expression profile may predict response to lenalidomide in patients who lack the deletion of 5q31.1. Tools such as ...

    Research Article last updated 07/20/2018 - 5:14pm.

  4. Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.

    ... supportive care alone, cytotoxic therapy, lenalidomide , histone deacetylase inhibitors, and HSCT, favorable ...

    Research Article last updated 07/20/2018 - 5:15pm.

  5. Treatment of myelodysplastic syndromes in elderly patients.

    ... is essential. Likewise, immunomodulatory drugs, such as lenalidomide , can reduce transfusion requirements and reverse cytologic ...

    Research Article last updated 07/20/2018 - 5:14pm.

  6. The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes

    ... and del(5q) (P=0.10) cases with controls. Median lenalidomide response duration increased proportionate to C-allele dosage ...

    Research Article last updated 07/20/2018 - 5:15pm.

  7. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management

    ... therapies include growth factor support, lenalidomide , hypomethylating agents, intensive chemotherapy , and allogeneic stem cell transplantation. The use of lenalidomide has significant clinical activity in patients with lower risk ...

    Research Article last updated 07/20/2018 - 5:14pm.

  8. Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management

    ... therapies include growth factor support, lenalidomide , hypomethylating agents, intensive chemotherapy , and allogeneic stem cell transplantation. The use of lenalidomide has significant clinical activity in patients with lower risk ...

    Research Article last updated 07/20/2018 - 5:15pm.

  9. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management

    ... therapies include growth factor support, lenalidomide , hypomethylating agents, intensive chemotherapy , and allogeneic stem cell transplantation. The use of lenalidomide has significant clinical activity in patients with lower risk ...

    Research Article last updated 07/20/2018 - 5:14pm.

  10. TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression.

    ... The probability of a complete cytogenetic response to lenalidomide was lower in mutated patients (0 of 7 v 12 of 24; P = .024). ...

    Research Article last updated 07/20/2018 - 5:14pm.